Correction to: Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer

Correction to: Cancer Immunology, Immunotherapy (2023) 72:409–425 10.1007/s00262-022-03238-w

In the article by Chen et al. in the Feb 2023 issue of Cancer Immunology Immunotherapy (“Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer” [pages 409–425]), the images captured by the microscope of Fig. 3C were incorrect due to the mistaken images being inadvertently inserted during the assembly of Fig. 3. The panels of Fig. 3C have been updated with the correct data. These errors do not affect the results or conclusions of this article. The corrected Fig. 3 is reproduced below.

Fig. 3.

Tumor cells elimination capacity in vitro. A Detection of MSLN expression in five human cell lines, including HEK293, Huh7, Hela, Skov3 and Ovcar-3 cells by flow cytometry. Cells were incubated with anti-MSLN antibody (blue) or its corresponding isotype control (red). Same below. B A real-time cytotoxicity assay (xCELLigence RTCA SP) was used to evaluate the lysis of the indicated tumor cells. Tumor cells treated with mock CAR-T (E⁻) cells or MSLN CAR-T (E⁺) cells at the indicated E/T ratios over a 50-h period. The NC group did not add other cells to co-incubate as a control. Same below. C Lysis of spheres of target ovarian cancer cell cultures in the presence of anti-MSLN CAR-T cells at different effector:target ratios (E:T). (Scale bar: 200 μm). D The release of cytokines of tumor cells after co-cultivation with anti-MSLN CAR-T cells. (n = 3) E Lentivirus-mediated MSLN overexpression in HEK293 cell line by flow cytometry. F The real-time cytotoxicity assay is used to evaluate the lysis of MSLN CAR-T on HEK293^MSLN+ cells. Mean ± SD; two-way ANOVA, ^***P < 0.001, ^****P < 0.0001

The authors would like to apologize for any inconvenience caused to the readers by these changes.